Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

968 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
Essink BJ, Shapiro C, Isidro MGD, Bradley P, Pragalos A, Bloch M, Santiaguel J, Frias MV, Miyakis S, Alves de Mesquita M, Berrè S, Servais C, Waugh N, Hoffmann C, Baba E, Schönborn-Kellenberger O, Wolz OO, Koch SD, Ganyani T, Boutet P, Mann P, Mueller SO, Ramanathan R, Gaudinski MR, Vanhoutte N. Essink BJ, et al. Among authors: bloch m. Hum Vaccin Immunother. 2024 Dec 31;20(1):2408863. doi: 10.1080/21645515.2024.2408863. Epub 2024 Oct 18. Hum Vaccin Immunother. 2024. PMID: 39422261 Free PMC article. Clinical Trial.
Randomized, placebo-controlled, phase I/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjects.
Emery S, Workman C, Puls RL, Bloch M, Baker D, Bodsworth N, Anderson J, Crowe SM, French MA, Hoy J, Aichelburg A, Ward LD, Boyle DB, Law MG, Kelleher AD, Cooper DA. Emery S, et al. Among authors: bloch m. Hum Vaccin. 2005 Nov-Dec;1(6):232-8. doi: 10.4161/hv.1.6.2342. Epub 2005 Nov 12. Hum Vaccin. 2005. PMID: 17012863 Clinical Trial.
The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse).
Bloch MT, Smith DE, Quan D, Kaldor JM, Zaunders JJ, Petoumenos K, Irvine K, Law M, Grey P, Finlayson RJ, McFarlane R, Kelleher AD, Carr A, Cooper DA. Bloch MT, et al. J Acquir Immune Defic Syndr. 2006 Jun;42(2):192-202. doi: 10.1097/01.qai.0000219779.50668.e6. J Acquir Immune Defic Syndr. 2006. PMID: 16688094 Clinical Trial.
Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study.
van Lunzen J, Antinori A, Cohen CJ, Arribas JR, Wohl DA, Rieger A, Rachlis A, Bloch M, Segal-Maurer S, Garner W, Porter D, Bosse M, Piontkowsky D, Chuck SK, De-Oertel S. van Lunzen J, et al. Among authors: bloch m. AIDS. 2016 Jan;30(2):251-9. doi: 10.1097/QAD.0000000000000911. AIDS. 2016. PMID: 26684822 Clinical Trial.
968 results